Advertisement

PentaVision

Retinal Physician

Article

Axpaxli Superior to Aflibercept in Wet AMD Trial

Data from the phase 3 SOL-1 trial showed that Ocular Therapeutix’s intravitreal insert outperformed the standard of care, providing sustained visual maintenance and fluid control in treatment-naïve patients.

Jim Gallagher, senior managing editor
Retinal Physician February 17, 2026
5 Key Takeaways

  • 1

    Axpaxli outperformed aflibercept in the phase 3 SOL-1 trial for wet AMD, demonstrating superior visual acuity maintenance and fluid control.

  • 2

    The trial showed 74.1% of Axpaxli-treated patients maintained vision at week 36, compared to 55.8% for aflibercept, a significant risk difference.

  • 3

    Axpaxli also demonstrated superior anatomic outcomes, with 55.9% of patients maintaining central subfield thickness within 30 μm of baseline at week 36.

  • 4

    Safety data indicated Axpaxli was well tolerated, with no serious ocular adverse events reported during the trial.

  • 5

    Ocular Therapeutix plans to submit a new drug application to the FDA for Axpaxli through an accelerated pathway based on SOL-1 trial results.